Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
mi
from
Shreveport, LA
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
mi
from
Shreveport, LA
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Werner-Francis Urology Associates, LLC
mi
from
Greenbelt, MD
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Werner-Francis Urology Associates, LLC
mi
from
Greenbelt, MD
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Lahey Clinic Medical Center - Burlington
mi
from
Burlington, MA
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Lahey Clinic Medical Center - Burlington
mi
from
Burlington, MA
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Nevada Cancer Institute
mi
from
Las Vegas, NV
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Community Care Physicians, PC at Urological Institute of NENY
mi
from
Albany, NY
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Community Care Physicians, PC at Urological Institute of NENY
mi
from
Albany, NY
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Our Lady of Mercy Medical Center Comprehensive Cancer Center
mi
from
Bronx, NY
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Our Lady of Mercy Medical Center Comprehensive Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Accumed Research Associates
mi
from
Garden City, NY
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Accumed Research Associates
mi
from
Garden City, NY
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Hudson Valley Urology
mi
from
Poughkeepsie, NY
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Hudson Valley Urology
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Alliance Urology Specialists - Greensboro
mi
from
Greensboro, NC
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Alliance Urology Specialists - Greensboro
mi
from
Greensboro, NC
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Riverside Methodist Hospital Cancer Care
mi
from
Columbus, OH
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Riverside Methodist Hospital Cancer Care
mi
from
Columbus, OH
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Urological Associates of Lancaster, Limited
mi
from
Lancaster, PA
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Urological Associates of Lancaster, Limited
mi
from
Lancaster, PA
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Urology Associates
mi
from
Nashville, TN
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Urology Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Mary Crowley Medical Research Center at Sammons Cancer Center
mi
from
Dallas, TX
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Mary Crowley Medical Research Center at Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Urology Associates of South Texas,PA
mi
from
McAllen, TX
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Urology Associates of South Texas,PA
mi
from
McAllen, TX
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Urology San Antonio, PA - Fredericksburg
mi
from
San Antonio, TX
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Urology San Antonio, PA - Fredericksburg
mi
from
San Antonio, TX
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated:  12/31/1969
Instituto Alexander Fleming
mi
from
Cramer,
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)
Status: Enrolling
Updated: 12/31/1969
Instituto Alexander Fleming
mi
from
Cramer,
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Helen F. Graham Cancer Center at Christiana Hospital
mi
from
Newark, DE
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Helen F. Graham Cancer Center at Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
MBCCOP - Howard University Cancer Center
mi
from
Washington,
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
MBCCOP - Howard University Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Central Illinois
mi
from
Decatur, IL
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
mi
from
Shreveport, LA
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Feist-Weiller Cancer Center at Louisiana State University Health Sciences
mi
from
Shreveport, LA
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Michigan Cancer Research Consortium
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Beaumont
mi
from
Royal Oak, MI
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Beaumont
mi
from
Royal Oak, MI
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - St. Louis-Cape Girardeau
mi
from
Saint Louis, MO
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - St. Louis-Cape Girardeau
mi
from
Saint Louis, MO
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Research for the Ozarks
mi
from
Springfield, MO
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Research for the Ozarks
mi
from
Springfield, MO
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Alamance Cancer Center at Alamance Regional Medical Center
mi
from
Burlington, NC
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Alamance Cancer Center at Alamance Regional Medical Center
mi
from
Burlington, NC
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hugh Chatham Memorial Hospital
mi
from
Elkin, NC
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hugh Chatham Memorial Hospital
mi
from
Elkin, NC
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Southeast Cancer Control Consortium
mi
from
Goldsboro, NC
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Leo W. Jenkins Cancer Center at ECU Medical School
mi
from
Greenville, NC
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Greenville
mi
from
Greenville, SC
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
South Carolina Cancer Specialists
mi
from
Hilton Head Island, SC
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
South Carolina Cancer Specialists
mi
from
Hilton Head Island, SC
Click here to add this to my saved trials
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated:  12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer
Status: Enrolling
Updated: 12/31/1969
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status: Enrolling
Updated:  12/31/1969
UT Southwestern
mi
from
Dallas, TX
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status: Enrolling
Updated: 12/31/1969
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Survivorship Promotion In Reducing IGF-1 Trial
Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins ProHealth
mi
from
Baltimore, MD
Survivorship Promotion In Reducing IGF-1 Trial
Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins ProHealth
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials